Takeaway
The severity of spinal muscular atrophy (SMA) is associated with serum creatine (Crn) levels; thus, Crn could be used as a biomarker for disease progression in SMA.
Why this matters
Simple biomarkers that can monitor SMA disease onset, progression and treatment response are currently lacking.
In the future, the measurement of Crn should be part of routine analysis and monitoring of people with SMA.